Twist Bioscience Corporation

Twist Bioscience Corporation, a for-profit synthetic biology manufacturer based in South San Francisco, California, operates as a prime contractor supplying custom DNA synthesis, oligonucleotide libraries, reagent kits, and molecular biology services to federal research and public health agencies on a full-and-open basis with no set-aside designations. The company competes across purchase orders and definitive contracts issued directly by NIH institutes, CDC, VA, and other federal customers, with 87% of its recent award footprint as prime contractor work.

Twist Bioscience's federal capability portfolio centers on synthetic DNA manufacturing, custom capture panels for genomic research, methylome sequencing and analysis services, library preparation kits, and specialized reagents for high-throughput genotyping and disease diagnostics. Recent representative awards include a $5 million definitive contract with the National Heart, Lung and Blood Institute (November 2021) for development of a portable, rapid COVID-19 diagnostic test using synthetic antibodies under the RADX TECH PROJECT; a $97 thousand equipment purchase from an unspecified federal headquarters division (June 2026); a $64 thousand contract with Veterans Integrated Service Network 22 (July 2024) for Formalin Fixed Paraffin Embedded methylome sample processing supporting VA lymphoid malignancies research; and a $157 thousand CDC Pittsburgh purchase order (September 2024) for lab supplies. The company also supplies methylation custom probes for DNA sequencing to the National Institute of Environmental Health Sciences (July 2026) and methylome sample processing services to VA Long Beach (June 2026, $47 thousand).

Customer concentration is diffuse across NIH institutes and federal health agencies. The top five customers by award count account for 58% of recent awards, led by CDC Pittsburgh (9 awards, $1.6 million combined potential value) and the National Institute of Allergy and Infectious Diseases (7 awards, $256 thousand). By potential value, however, the National Heart, Lung and Blood Institute dominates with $5 million across 2 awards—the $5 million COVID-19 diagnostic contract being the anchor—followed by the Defense Advanced Research Projects Agency with $4.5 million on one award. CDC Pittsburgh's nine smaller purchases comprise $1.6 million, and VA and NIAID follow. The vendor has worked with 18 distinct federal agencies, spanning NIH components (NHLBI, NIAID, NHGRI, NINDS, NCI, NIDDK, NIA), CDC, VA, DHS Science and Technology Directorate, Department of the Air Force, and DARPA. No parent IDIQs or government-wide vehicles are evident in the source; awards are direct purchase orders and definitive contracts.

Activity has accelerated in recent years. The vendor received 5 awards in 2022 and 2023 respectively, surged to 11 awards in 2024 (driven partly by smaller NIH institute and CDC purchases), then moderated to 5 awards each in 2025 and 2026. Combined potential value across all 45 awards totals $12.2 million, though combined dollars obligated reached $13.2 million (108% of potential value), suggesting some awards have been modified upward. Recompete exposure in the next twenty-four months is minimal—only one award ($47 thousand) completes by October 2028. Award categorization reflects the manufacturing footprint: 23 awards fall under research and development in biotechnology; 7 under biological product manufacturing; 5 under additional biotechnology R&D; and 4 under analytical laboratory instrument manufacturing. PSC codes track laboratory equipment and supplies (14 awards), drugs and biologicals (7), and reference laboratory testing (7).

Twist Bioscience's subcontractor presence is limited but strategically positioned in federal research infrastructure. The company supplies custom panels and library preparation kits to Battelle National Biodefense Institute under DHS contract HSHQDC-15-C-00064 for the National Biodefense Analysis and Countermeasures Center (NBACC) FFRDC at Fort Detrick, Maryland, across multiple awards spanning 2024 through 2026 totaling approximately $200 thousand combined. It also received a sub-award from Purdue University (June 2025) as part of an NSF Ideas Lab effort on programmable small molecule biosynthesis. The subcontract footprint reflects the vendor's role as a specialized reagent and synthesis supplier to larger research contractors and academic recipients rather than as a systems integrator or primary research performer. Federal grant sub-awards are sparse; the company functions principally as a materials and services vendor rather than as a grant recipient or collaborative researcher.